Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Ralf‐Dieter Hofheinz(University of Mannheim), Erika Martinelli(University of Campania "Luigi Vanvitelli"), Geke A.P. Hospers(University Medical Center Groningen), Rodrigo Oliva Perez(Hospital Alemão Oswaldo Cruz), E Fokas(Düsseldorf University Hospital), Irıs D. Nagtegaal(Radboud University Nijmegen), Marianne G. Guren(Oslo University Hospital), Dirk Arnold(Asklepios Klinik Altona), A. Cervantes(INCLIVA Health Research Institute), Timothy Price(Basil Hetzel Institute), S. Lonardi(Istituto Oncologico Veneto), Regina G. H. Beets‐Tan(Maastricht University), Léonor Benhaïm(Institut Gustave Roussy)
Cited by 122
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k